Covered recipient · General Payments record
CHACE MICHAEL DAVIES
Allopathic & Osteopathic Physicians Emergency Medicine
General Payments · PY2023–2024
$1,287.92
- Reported across 15 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $882.48 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $246.58 | 2 |
| Acerta Pharma LLC | $243.68 | 2 |
| ABBVIE INC. | $130.98 | 2 |
| Novo Nordisk AS | $124.60 | 1 |
| Arcutis Biotherapeutics, Inc. | $111.26 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.38 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $6.24 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103606432 | CMS |
| ABBVIE INC. | $124.74 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103606434 | CMS |
| Arcutis Biotherapeutics, Inc. | $111.26 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1121039286 | CMS |
| AstraZeneca Pharmaceuticals LP | $121.84 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105460626 | CMS |
| AstraZeneca Pharmaceuticals LP | $121.84 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105832485 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.38 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118233240 | CMS |
| GENZYME CORPORATION | $124.74 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139991245 | CMS |
| GENZYME CORPORATION | $121.84 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139991273 | CMS |
| Novo Nordisk Inc | $124.60 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097707847 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.